I have told you don’t send to me messages. —— Sent from PB to little tchalla ——— Re: tchalla post# 8610 Friday, 08/25/2023 12:47:36 AM Never engage a basher but in this case, I decide to feed the dog. The problem is you change your mind very often. Quote from last weeks, you said:. https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172680985 ————-
Can you make up your mind? Very sad you can't decide to go long or short with your investment. You are clueless don't understand a basic of an investment. Do you know the reason people are investing in this biotech stock is not solely based on its current offerings, but rather the immense potential it holds. With a series of anticipated news and press releases during the month March and April, along with the addition of new board members, licensing agreements for innovative products with patents valued at over $750 million, and upcoming spin-off plans, there is a significant buzz around the company. Additionally, the company's connection to artificial intelligence further adds to its allure.
Moreover, if you take a look at the bios of the board advisers, you'll see that they are highly esteemed in their respective fields. To be frank, if you can't recognize this, I can't help with that level of ignorance. https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172681127
Do you really think all these fools...the CEO, CFO, COO, and the entire directors are sacrificing for nothing?
Item 11. Executive Compensation We have employment agreements with our Chief Executive Officer, President and Chief Financial Officer, each of whom was to be compensated by stock grants accrued monthly based on current share prices or block grants during the period ended December 31, 2022. In consideration of the Company’s financial performance and lack of liquidity during this period, each of our officers waived compensation and we adjusted compensation accordingly.
During the six months ended June 30, 2023, Dr. Edward E. Jacobs, M.D., our CEO, advanced $51,044 for operating expenses. As of June 30, 2023 and December 31, 2022, the Company recorded due to related party of $52,846 and $1,802, respectively.
Furthermore, the CEO is not only not taking a salary but also personally funding the company for its working capital needs. This level of dedication and commitment to the company's success is too extraordinary and improbable to be believed.
During the six months ended June 30, 2023, Dr. Edward E. Jacobs, M.D., our CEO, advanced $51,044 for operating expenses. As of June 30, 2023 and December 31, 2022, the Company recorded due to related party of $52,846 and $1,802, respectively.
The entire management team does not get compensation since April 2019. This rarity is unlike anything I've seen before. It's impressive that they have waived their compensation, demonstrating their commitment to retaining earnings and not simply seeking to scam our money. This is precisely why I'm dedicated to pushing forward and consistently providing thorough information for everyone to make the right choice. ITEM 6. EXECUTIVE COMPENSATION. Up to April 30, 2019, the following officers and director have received cash and restricted stock awards as compensation for Services since the Company’s inception. However, as of September 2018 and until the Company acquires additional capital, it is not anticipated that any officer or director will receive salary compensation from the Company other than reimbursement for out-of-pocket expenses incurred on behalf of the Company
If you're not interested in this stock, then it's best for you to move on. Don't waste my valuable time and the time of other stakeholders here with your nonsensical, pathetic, and senseless remarks.
News 
Market Data 
Discover 
